Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Advanced Osteolytic Lesions (OL), Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM)

Mariam M Boota, MD, Rashid Z Khan, MD, Eric R Rosenbaum, MD MPH, Ahmed Abuabdou, MD, Chris W Williams, Bart Barlogie, MD PhD, Michele Cottler-Fox, MD

Blood (2014) 124 (21): 3858.

https://doi.org/10.1182/blood.V124.21.3858.3858

Published: 2014

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Alan Mitchell, Donald Johann, MD MS, Kelly Robbins, Ryan K Van Laar, PhD, Siraj Ali, MDPhD, Vincent A. Miller, MD, Clyde Bailey, Jeffery Sawyer, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 4775.

https://doi.org/10.1182/blood.V124.21.4775.4775

Published: 2014

Journal Articles

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Frits van Rhee, MD PhD, Alan Mitchell, Christoph Heuck, MD, Monica Grazziutti, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 1199.

https://doi.org/10.1182/blood.V124.21.1199.1199

Published: 2014

Journal Articles

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Rashid Z Khan, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Xenofon Papanikolaou, MD, Caleb K Stein, MS, Adam Rosenthal, Christoph Heuck, MD, Frits van Rhee, MD PhD, Jameel Muzaffar, MD, Maurizio Zangari, MD, Clyde Bailey, Phillip Farmer, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 5770.

https://doi.org/10.1182/blood.V124.21.5770.5770

Published: 2014

Journal Articles

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

Christoph Heuck, MD, Donald Johann, MD MS, Brian A Walker, PhD, Caleb K Stein, MS, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Ruslana Tytarenko, Phillip Farmer, Ryan Williams, Siraj Ali, MDPhD, Phil J Stephens, PhD, Vincent A. Miller, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3418.

https://doi.org/10.1182/blood.V124.21.3418.3418

Published: 2014

Journal Articles

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Yogesh Jethava, MB, MRCP, MD FRCPath, Rachel Hunter-Merrill, Gareth J Morgan, MD PhD, Rashid Z Khan, MD, Aasiya Matin, MD, Christoph Heuck, MD, Maurizio Zangari, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3407.

https://doi.org/10.1182/blood.V124.21.3407.3407

Published: 2014

Journal Articles

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Maurizio Zangari, MD, Caleb K Stein, MS, Shmuel Yaccoby, PhD, Donghoon Yoon, PhD, Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Donald Johann, MD MS, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3409.

https://doi.org/10.1182/blood.V124.21.3409.3409

Published: 2014

Journal Articles

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Rashid Z Khan, MD, Christoph Heuck, MD, Adam Rosenthal, Caleb K Stein, MS, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Xenofon Papanikolaou, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Frits Van Rhee, Madhav V. Dhodapkar, MD, Gareth J Morgan, MD PhD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2078.

https://doi.org/10.1182/blood.V124.21.2078.2078

Published: 2014

Journal Articles

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Xenofon Papanikolaou, MD, Adam Rosenthal, Rashid Z Khan, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Omar Atiq, MD, Sarah Waheed, MD, Faith Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2079.

https://doi.org/10.1182/blood.V124.21.2079.2079

Published: 2014

Journal Articles

Risk Of Myelodysplastic Syndrome (MDS) After Hematopoietic Progenitor Cell Collection Using Plerixafor

Rashid Z Khan, MD, Eric R Rosenbaum, MD, MPH, Mariam M Boota, Saad Z Usmani, MD, FACP, Bart Barlogie, MD, PhD, Michele Cottler-Fox, M.D.

Blood (2013) 122 (21): 4650.

https://doi.org/10.1182/blood.V122.21.4650.4650

Published: 2013

Journal Articles

Contrasting patterns of DNA strand breakage and ADP-ribosylation- dependent DNA ligation during granulocyte and monocyte differentiation

Z Khan, GE Francis

Blood (1987) 69 (4): 1114–1119.

https://doi.org/10.1182/blood.V69.4.1114.1114

Published: 1987

NARROW

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Advanced Osteolytic Lesions (OL), Mobilization and Collection of Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM)

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Risk Of Myelodysplastic Syndrome (MDS) After Hematopoietic Progenitor Cell Collection Using Plerixafor

Contrasting patterns of DNA strand breakage and ADP-ribosylation- dependent DNA ligation during granulocyte and monocyte differentiation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only